Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cardax, Inc. (OTC: CDXI).

Full DD Report for CDXI

You must become a subscriber to view this report.


Recent News from (OTC: CDXI)

Cardax Reports Q2 2018 Results
HONOLULU , Aug. 13, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today announced its results for the second quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased more than four times, to $27...
Source: PR Newswire
Date: August, 13 2018 17:00
Cardax Announces Successful Completion of Warrant Exchange Offer
HONOLULU , July 30, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it successfully closed its warrant exchange offer (" Exchange Offer ") on Friday, July 27, 2018 , at 5:00 p.m., Eastern Daylight Time . The Exchange Offer allowed holders of Cardax $0.625 war...
Source: PR Newswire
Date: July, 30 2018 08:00
Cardax Announces Extension of Warrant Exchange Offer to July 27, 2018
HONOLULU , July 23, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it is extending to  July 27, 2018 ,  the period for its offer (" Exchange Offer ") to allow holders of warrants for its common stock that have an exercise price of $0.625 and expire ...
Source: PR Newswire
Date: July, 23 2018 17:00
Cardax Announces Effectiveness of Registration Statement and Commencement of Warrant Exchange Offer
HONOLULU , June 22, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that the Securities and Exchange Commission has declared effective the Company's Registration Statement on Form S-4 in connection with a one-time offer to allow holders of its $0.625 warrants ...
Source: PR Newswire
Date: June, 22 2018 13:52
Cardax Engages Industry Veteran Fred Sancilio, Ph.D., to Launch Orphan Drug Development Program
HONOLULU , June 13, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it engaged industry veteran and orphan drug expert, Frederick D. Sancilio , Ph.D., to launch the Company's orphan drug development program. Dr. Sancilio has over 40 years of pharmaceutical indus...
Source: PR Newswire
Date: June, 13 2018 08:00
Cardax Adds Makarand Jawadekar, Ph.D., and Elona Kogan to its Board of Directors
HONOLULU , June 1, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that Makarand Jawadekar, Ph.D., and Elona Kogan joined its Board of Directors, effective June 1, 2018 . Dr. Jawadekar spent 28 years at Pfizer Inc. in diverse roles, combining both technical and m...
Source: PR Newswire
Date: June, 01 2018 08:00
Cardax reports Q1 results
Cardax ( OTCQB:CDXI ): Q1 EPS of -$0.01 More news on: Cardax, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 08:10
Cardax Reports Q1 2018 Results
HONOLULU , May 9, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced its results for the first quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased almost three-fold from $107,990 in Q...
Source: PR Newswire
Date: May, 09 2018 08:00
Cardax Announces Warrant Exchange Offer
HONOLULU , May 2, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission in connection with a one-time offer to allow holders of its $0.625 warrants expiring in February 201...
Source: PR Newswire
Date: May, 02 2018 17:26
Cardax reports FY results
Cardax ( OTCQB:CDXI ): FY EPS of -$0.02 More news on: Cardax, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 27 2018 08:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.20050.200.20050.202,758
2018-12-120.20250.2150.2150.202518,875
2018-12-110.200.200.200.205,000
2018-12-100.200.200.200.201,725
2018-12-070.195250.1950.200.1951,500

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-132,1582,75878.2451Short
2018-12-1210,00018,87552.9801Short
2018-12-112,5005,00050.0000Short
2018-12-0329,80034,80085.6322Short
2018-11-2938,20087,35043.7321Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CDXI.


About Cardax, Inc. (OTC: CDXI)

Logo for Cardax, Inc. (OTC: CDXI)

Cardax devotes substantially all of its efforts to developing and commercializing safe anti inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti inflammatory without the side effects of currently marketed anti inflammatories. The safety and efficacy of Cardax s products have not been directly evaluated in clinical trials or confirmed by the FDA.

 

 

 

Current Management

  • David G. Watumull / CEO, President
  • David M. Watumull / COO, Asst. Treasurer, Asst. Secretary
  • John B. Russell / CFO, Treasurer
  • Richard M. Morris / Secretary
  • George W. Bickerstaff, III / Chairman
  • Michele Galen /
  • Terence A. Kelly, Ph.D. /
  • David G. Watumull /

Current Share Structure

  • Market Cap: $42,813,406 - 03/15/2018
  • Authorized: 400,000,000 - 03/01/2018
  • Issue and Outstanding: 122,674,516 - 03/01/2018
  • Float: 3,345,914 - 03/12/2015

 


Recent Filings from (OTC: CDXI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Registration of securities issued in business combination transactions
Filing Type: S-4Filing Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 05 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 13 2017
Filing Type: CT ORDERFiling Source: edgar
Filing Date: November, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 20 2017

 

 


Daily Technical Chart for (OTC: CDXI)

Daily Technical Chart for (OTC: CDXI)


Stay tuned for daily updates and more on (OTC: CDXI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CDXI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CDXI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CDXI and does not buy, sell, or trade any shares of CDXI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/